Tesamorelin Effects on Liver Fat and Histology in HIV
Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative UO1 Grant
Sponsor: Massachusetts General Hospital
This NA trial investigates Human Immunodeficiency Virus (HIV) and Nonalcoholic Fatty Liver Disease (NAFLD) and is currently completed. Massachusetts General Hospital leads this study, which shows 12 recorded versions since 2015 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
-
Jan 2021 — Dec 2022 [monthly]
Completed NA
▶ Show 7 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Apr 2019 — Feb 2020 [monthly]
Active Not Recruiting NA
-
Nov 2018 — Apr 2019 [monthly]
Active Not Recruiting NA
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting NA
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Mar 2018 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Jul 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Massachusetts General Hospital
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .